<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460811</url>
  </required_header>
  <id_info>
    <org_study_id>MCP-103-202</org_study_id>
    <nct_id>NCT00460811</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</brief_title>
  <official_title>A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-range-finding, Parallel-design, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Irritable Bowel Syndrome With Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, efficacy, and dose response of a range
      of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>The change in the weekly normalized CSBM Rate during Weeks 1 through 12 of the Treatment Period from the weekly normalized CSBM Rate obtained during the Pretreatment Period.
The CSBM rate was normalized based on the number of CSBMs occurring in that week, adjusting for differences in the duration of the week and black-out periods (time not covered due to a missed IVRS call) versus 7x24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>For each week of the Treatment and Posttreatment Periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥ 4 days of IVRS questions, 2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from the baseline weekly CSBM rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Weekly Normalized SBM Rate for the Treatment Period</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>SBMs were measured daily during the treatment period by patient calls to the IVRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Stool Consistency (7-point Ordinal BSFS) for the Treatment Period</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Stool consistency analyses were performed using the 7-point Bristol Stool Form Scale (BSFS), whereby a score of 1 = separate hard lumps like nuts (difficult to pass); 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = watery, no solid pieces (entirely liquid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Straining (5-point Ordinal Scale) for the Treatment Period</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Degree of Relief of Irritable Bowel Syndrome (IBS) Symptoms (7-point Balanced Scale) for the Treatment Period</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Patients provided a weekly assessment of Degree of Relief of IBS Symptoms using a 7-point balanced scale (1=completely relieved, 2=considerably relieved, 3=somewhat relieved, 4=unchanged, 5=somewhat worse, 6=considerably worse, 7=as bad as I can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Abdominal Pain (5-point Ordinal Scale) for the Treatment Period</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>During the study, patients provided their self assessment of abdominal pain using a 5-point ordinal scale (1=none, 2=mild, 3=moderate, 4=severe, 5=very severe</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Irritable Bowel Syndrome With Constipation</condition>
  <arm_group>
    <arm_group_label>72 ug linaclotide acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>145 ug linaclotide acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>290 ug linaclotide acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>579 ug linaclotide acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linaclotide Acetate</intervention_name>
    <description>Oral, once daily</description>
    <arm_group_label>72 ug linaclotide acetate</arm_group_label>
    <arm_group_label>145 ug linaclotide acetate</arm_group_label>
    <arm_group_label>290 ug linaclotide acetate</arm_group_label>
    <arm_group_label>579 ug linaclotide acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Oral, once daily</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must not be pregnant or breastfeeding and agree to use birth control;

          -  Completion of a negative colonoscopy as per American Gastroenterology Association
             (AGA) criteria and no clinically-significant laboratory or physical examination
             findings;

          -  Meets protocol-defined criteria for IBS-C, including stool frequency, straining, stool
             consistency, abdominal pain, and abdominal discomfort criteria;

          -  Demonstrates English fluency and has access to a touch-tone telephone.

        Exclusion Criteria:

          -  Recent history of mushy or watery stools;

          -  Various medical conditions, medical histories, or family medical histories that would
             not make the patient a good candidate for the study;

          -  Clinically-significant alarm symptoms;

          -  Secondary causes of constipation or evacuation disorders;

          -  Surgery to the gastrointestinal tract;

          -  Usage of prohibited medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Microbia Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Microbia, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Sherwood</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>60601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Mission</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Shawnee</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Blackwood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Pittsford</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Elkin</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Harrisburg</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Levittown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>LaCrosse</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Abbortsford</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Milton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Microbia Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2007</study_first_submitted>
  <study_first_submitted_qc>April 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2007</study_first_posted>
  <results_first_submitted>September 28, 2012</results_first_submitted>
  <results_first_submitted_qc>December 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2013</results_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome with Constipation</keyword>
  <keyword>IBS</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>linaclotide acetate</keyword>
  <keyword>linaclotide</keyword>
  <keyword>MD-1100</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment occurred over a 12 month period from March 2007 to February 2008 at 92 US study sites.</recruitment_details>
      <pre_assignment_details>Patients went through a 14 to 17 day Pretreatment Period during which the patients provided qualifying bowel habit and symptoms, and rescue medicine usage information through an interactive voice response system (IVRS).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>72 μg Linaclotide Acetate</title>
          <description>Linaclotide, 72μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P2">
          <title>145 μg Linaclotide Acetate</title>
          <description>Linaclotide, 145μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P3">
          <title>290 μg Linaclotide Acetate</title>
          <description>Linaclotide, 290μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P4">
          <title>579 μg Linaclotide Acetate</title>
          <description>Linaclotide, 579μg dose, oral administration, once per day</description>
        </group>
        <group group_id="P5">
          <title>Matching Placebo</title>
          <description>Dose-matched placebo, oral administration, once per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="89"/>
                <participants group_id="P5" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>72 µg Linaclotide Acetate</title>
          <description>Linaclotide, 72μg dose, oral administration, once per day</description>
        </group>
        <group group_id="B2">
          <title>145 µg Linaclotide Acetate</title>
          <description>Linaclotide, 145μg dose, oral administration, once per day</description>
        </group>
        <group group_id="B3">
          <title>290 µg Linaclotide Acetate</title>
          <description>Linaclotide, 290μg dose, oral administration, once per day</description>
        </group>
        <group group_id="B4">
          <title>579 µg Linaclotide Acetate</title>
          <description>Linaclotide, 579μg dose, oral administration, once per day</description>
        </group>
        <group group_id="B5">
          <title>Matching Placebo</title>
          <description>Dose-matched placebo, oral administration, once per day</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="85"/>
            <count group_id="B4" value="89"/>
            <count group_id="B5" value="85"/>
            <count group_id="B6" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="12.5"/>
                    <measurement group_id="B2" value="45.6" spread="10.8"/>
                    <measurement group_id="B3" value="45.8" spread="11.4"/>
                    <measurement group_id="B4" value="43.7" spread="11.4"/>
                    <measurement group_id="B5" value="44.3" spread="11.3"/>
                    <measurement group_id="B6" value="44.4" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 years to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="85"/>
                    <measurement group_id="B6" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Older than 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="78"/>
                    <measurement group_id="B6" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="81"/>
                    <measurement group_id="B6" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period</title>
        <description>The change in the weekly normalized CSBM Rate during Weeks 1 through 12 of the Treatment Period from the weekly normalized CSBM Rate obtained during the Pretreatment Period.
The CSBM rate was normalized based on the number of CSBMs occurring in that week, adjusting for differences in the duration of the week and black-out periods (time not covered due to a missed IVRS call) versus 7x24 hours.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <population>The Intent-to-treat (ITT) Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency)</population>
        <group_list>
          <group group_id="O1">
            <title>72 ug Linaclotide Acetate</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>145 ug Linaclotide Acetate</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>290 ug Linaclotide Acetate</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>579 ug Linaclotide Acetate</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period</title>
          <description>The change in the weekly normalized CSBM Rate during Weeks 1 through 12 of the Treatment Period from the weekly normalized CSBM Rate obtained during the Pretreatment Period.
The CSBM rate was normalized based on the number of CSBMs occurring in that week, adjusting for differences in the duration of the week and black-out periods (time not covered due to a missed IVRS call) versus 7x24 hours.</description>
          <population>The Intent-to-treat (ITT) Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency)</population>
          <units>CSBMs per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="0.385"/>
                    <measurement group_id="O2" value="2.49" spread="0.380"/>
                    <measurement group_id="O3" value="3.61" spread="0.372"/>
                    <measurement group_id="O4" value="2.68" spread="0.369"/>
                    <measurement group_id="O5" value="1.01" spread="0.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>For each of the 4 active linaclotide groups, the null hypothesis was that there was no difference between placebo and the dose group in the change from baseline in the weekly normalized CSBM Rate. An observed cases (OC) approach to missing post-baseline data was applied: any missing data were not imputed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>For each of the 4 active linaclotide groups, the null hypothesis was that there was no difference between placebo and the dose group in the change from baseline in the weekly normalized CSBM Rate. An observed cases (OC) approach to missing post-baseline data was applied: any missing data were not imputed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>For each of the 4 active linaclotide groups, the null hypothesis was that there was no difference between placebo and the dose group in the change from baseline in the weekly normalized CSBM Rate. An observed cases (OC) approach to missing post-baseline data was applied: any missing data were not imputed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>For each of the 4 active linaclotide groups, the null hypothesis was that there was no difference between placebo and the dose group in the change from baseline in the weekly normalized CSBM Rate. An observed cases (OC) approach to missing post-baseline data was applied: any missing data were not imputed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</title>
        <description>For each week of the Treatment and Posttreatment Periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥ 4 days of IVRS questions, 2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from the baseline weekly CSBM rate.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency).</population>
        <group_list>
          <group group_id="O1">
            <title>72 μg Linaclotide Acetate</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>145 μg Linaclotide Acetate</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>290 μg Linaclotide Acetate</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>579 μg Linaclotide Acetate</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</title>
          <description>For each week of the Treatment and Posttreatment Periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥ 4 days of IVRS questions, 2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from the baseline weekly CSBM rate.</description>
          <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Weekly Normalized SBM Rate for the Treatment Period</title>
        <description>SBMs were measured daily during the treatment period by patient calls to the IVRS.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency).</population>
        <group_list>
          <group group_id="O1">
            <title>72 ug Linaclotide Acetate</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>145 ug Linaclotide Acetate</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>290 ug Linaclotide Acetate</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>579 ug Linaclotide Acetate</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Weekly Normalized SBM Rate for the Treatment Period</title>
          <description>SBMs were measured daily during the treatment period by patient calls to the IVRS.</description>
          <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency).</population>
          <units>SBMs per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" spread="0.457"/>
                    <measurement group_id="O2" value="4.36" spread="0.453"/>
                    <measurement group_id="O3" value="4.97" spread="0.442"/>
                    <measurement group_id="O4" value="5.64" spread="0.439"/>
                    <measurement group_id="O5" value="1.68" spread="0.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Stool Consistency (7-point Ordinal BSFS) for the Treatment Period</title>
        <description>Stool consistency analyses were performed using the 7-point Bristol Stool Form Scale (BSFS), whereby a score of 1 = separate hard lumps like nuts (difficult to pass); 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = watery, no solid pieces (entirely liquid).</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency). 15 patients with no pretreatment spontaneous bowel movements were excluded from the Stool Consistency analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>72 μg Linaclotide Acetate</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>145 μg Linaclotide Acetate</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>290 μg Linaclotide Acetate</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>579 μg Linaclotide Acetate</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Stool Consistency (7-point Ordinal BSFS) for the Treatment Period</title>
          <description>Stool consistency analyses were performed using the 7-point Bristol Stool Form Scale (BSFS), whereby a score of 1 = separate hard lumps like nuts (difficult to pass); 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = watery, no solid pieces (entirely liquid).</description>
          <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency). 15 patients with no pretreatment spontaneous bowel movements were excluded from the Stool Consistency analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="0.133"/>
                    <measurement group_id="O2" value="1.80" spread="0.131"/>
                    <measurement group_id="O3" value="2.28" spread="0.127"/>
                    <measurement group_id="O4" value="2.20" spread="0.127"/>
                    <measurement group_id="O5" value="0.56" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Straining (5-point Ordinal Scale) for the Treatment Period</title>
        <description>Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency). 15 patients with no pretreatment spontaneous bowel movements were excluded from the Straining analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>72 μg Linaclotide Acetate</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>145 μg Linaclotide Acetate</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>290 μg Linaclotide Acetate</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>579 μg Linaclotide Acetate</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Straining (5-point Ordinal Scale) for the Treatment Period</title>
          <description>Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.</description>
          <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency). 15 patients with no pretreatment spontaneous bowel movements were excluded from the Straining analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="0.081"/>
                    <measurement group_id="O2" value="-1.20" spread="0.080"/>
                    <measurement group_id="O3" value="-1.48" spread="0.077"/>
                    <measurement group_id="O4" value="-1.35" spread="0.078"/>
                    <measurement group_id="O5" value="-0.71" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Degree of Relief of Irritable Bowel Syndrome (IBS) Symptoms (7-point Balanced Scale) for the Treatment Period</title>
        <description>Patients provided a weekly assessment of Degree of Relief of IBS Symptoms using a 7-point balanced scale (1=completely relieved, 2=considerably relieved, 3=somewhat relieved, 4=unchanged, 5=somewhat worse, 6=considerably worse, 7=as bad as I can imagine).</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency). 13 patients who dropped out prior to finishing 1 week of the trial have missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>72 μg Linaclotide Acetate</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>145 μg Linaclotide Acetate</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>290 μg Linaclotide Acetate</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>579 μg Linaclotide Acetate</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Degree of Relief of Irritable Bowel Syndrome (IBS) Symptoms (7-point Balanced Scale) for the Treatment Period</title>
          <description>Patients provided a weekly assessment of Degree of Relief of IBS Symptoms using a 7-point balanced scale (1=completely relieved, 2=considerably relieved, 3=somewhat relieved, 4=unchanged, 5=somewhat worse, 6=considerably worse, 7=as bad as I can imagine).</description>
          <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency). 13 patients who dropped out prior to finishing 1 week of the trial have missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="87"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="0.108"/>
                    <measurement group_id="O2" value="-1.37" spread="0.107"/>
                    <measurement group_id="O3" value="-1.66" spread="0.105"/>
                    <measurement group_id="O4" value="-1.49" spread="0.104"/>
                    <measurement group_id="O5" value="-0.81" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Abdominal Pain (5-point Ordinal Scale) for the Treatment Period</title>
        <description>During the study, patients provided their self assessment of abdominal pain using a 5-point ordinal scale (1=none, 2=mild, 3=moderate, 4=severe, 5=very severe</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency).</population>
        <group_list>
          <group group_id="O1">
            <title>72 μg Linaclotide Acetate</title>
            <description>Linaclotide, 72μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O2">
            <title>145 μg Linaclotide Acetate</title>
            <description>Linaclotide, 145μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O3">
            <title>290 μg Linaclotide Acetate</title>
            <description>Linaclotide, 290μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O4">
            <title>579 μg Linaclotide Acetate</title>
            <description>Linaclotide, 579μg dose, oral administration, once per day</description>
          </group>
          <group group_id="O5">
            <title>Matching Placebo</title>
            <description>Dose-matched placebo, oral administration, once per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Abdominal Pain (5-point Ordinal Scale) for the Treatment Period</title>
          <description>During the study, patients provided their self assessment of abdominal pain using a 5-point ordinal scale (1=none, 2=mild, 3=moderate, 4=severe, 5=very severe</description>
          <population>The ITT Population included 419 patients of the Safety Population who also had ≥ 1 post-dose evaluation of the primary efficacy assessment (i.e., CSBM Frequency).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.075"/>
                    <measurement group_id="O2" value="-0.71" spread="0.074"/>
                    <measurement group_id="O3" value="-0.90" spread="0.073"/>
                    <measurement group_id="O4" value="-0.86" spread="0.072"/>
                    <measurement group_id="O5" value="-0.49" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from March of 2007 to April 2008.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>72 µg Linaclotide Acetate</title>
          <description>Linaclotide, 72μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E2">
          <title>145 µg Linaclotide Acetate</title>
          <description>Linaclotide, 145μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E3">
          <title>290 µg Linaclotide Acetate</title>
          <description>Linaclotide, 290μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E4">
          <title>579 µg Linaclotide Acetate</title>
          <description>Linaclotide, 579μg dose, oral administration, once per day</description>
        </group>
        <group group_id="E5">
          <title>Matching Placebo</title>
          <description>Dose-matched placebo, oral administration, once per day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>medDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the PI is that publication cannot be made for 24 months from the date of final data lock of the study, the sponsor can review the publication prior to public release, sponsor requires a minimum 60 day review period for each publication, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request an additional delay period of 60 days in order to protect potentially patentable information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Doug Levine, MD</name_or_title>
      <organization>Ironwood Pharmaceuticals</organization>
      <phone>617.374.3906</phone>
      <email>dlevine@ironwoodpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

